Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

(2020) Maria Gavriatopoulou et al.   LEUKEMIA

Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities

(2020) Claudia A. M. Stege et al.   LEUKEMIA

Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial

(2020) Sandra Maria Dold et al.   HAEMATOLOGICA

Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age

(2020) Monika Engelhardt et al.   HAEMATOLOGICA

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

(2020) Shaji Kumar et al.   JOURNAL OF CLINICAL ONCOLOGY

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

(2020) Maria-Victoria Mateos et al.   Lancet Haematology

Defining the vulnerable patient with myeloma—a frailty position paper of the European Myeloma Network

(2020) Gordon Cook et al.   LEUKEMIA

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

(2020) Nagesh Kalakonda et al.   Lancet Haematology

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study

(2019) Gordon Cook et al.   Lancet Haematology

Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population

(2019) Saurabh Zanwar et al.   Current Hematologic Malignancy Reports

Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options

(2019) Harmen van Andel et al.   LEUKEMIA

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

(2019) Andrzej J. Jakubowiak et al.   BRITISH JOURNAL OF HAEMATOLOGY

miR-23b-3p suppressing PGC1α promotes proliferation through reprogramming metabolism in osteosarcoma

(2019) Ran Zhu et al.   Cell Death & Disease

Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma

(2019) Saad Z. Usmani et al.   BLOOD

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

(2019) Thierry Facon et al.   LEUKEMIA

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial

(2019) Charlotte Pawlyn et al.   LEUKEMIA

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma

(2018) Ujjawal H. Gandhi et al.   Clinical Lymphoma Myeloma & Leukemia

Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management

(2018) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

(2018) Nizar J. Bahlis et al.   BLOOD

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients

(2017) Monika Engelhardt et al.   HAEMATOLOGICA

XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy

(2017) Vincent Camus et al.   Journal of Hematology & Oncology

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

(2017) Brian G M Durie et al.   LANCET

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma

(2017) Mark E. Issa et al.   Clinical Epigenetics

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients

(2017) Monika Engelhardt et al.   HAEMATOLOGICA

N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma

(2016) Paolo Milani et al.   AMERICAN JOURNAL OF HEMATOLOGY

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Concise review ‐ Treatment of multiple myeloma in the very elderly: How do novel agents fit in?

(2016) Nicolas Kint et al.   Journal of Geriatric Oncology

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

(2015) A. Palumbo et al.   BLOOD

Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years

(2014) H W Auner et al.   BONE MARROW TRANSPLANTATION

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

(2013) S. Bringhen et al.   HAEMATOLOGICA

Assessment of Vulnerability Measures and Their Effect on Survival in a Real-Life Population of Multiple Myeloma Patients Registered at Marche Region Multiple Myeloma Registry

(2012) Massimo Offidani et al.   Clinical Lymphoma Myeloma & Leukemia